Glucagon-Like Peptide-1 Receptor Agonist Medications Alter Outcomes of Spine Surgery: A Study Among Over 15,000 Patients
- PMID: 39895110
- DOI: 10.1097/BRS.0000000000005283
Glucagon-Like Peptide-1 Receptor Agonist Medications Alter Outcomes of Spine Surgery: A Study Among Over 15,000 Patients
Abstract
Study design: Retrospective cohort study.
Objective: To investigate the relationship between perioperative glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and postoperative outcomes after spinal fusion in obese and diabetic patient populations.
Background: GLP-1 RAs have been shown to be beneficial when used perioperatively in clinical orthopedic arthroplasty literature. Minimal evidence exists showing efficacy with respect to spinal fusion.
Materials and methods: This retrospective, multi-center study accessed the TriNetX platform, using the research database to identify diabetic patients who underwent spinal fusion between 2008 and 2022. Cohorts were created based on body mass index and GLP-1 RA usage. Propensity score matching was employed to create balanced cohorts utilizing body mass index, hemoglobin A1c, surgical intervention, as well as other demographic characteristics. Orthopedic outcomes were compared between GLP-1 RA users and non-users. The primary outcomes included postoperative infection, readmission, revision surgery, and quality of life metrics.
Results: After matching, the study cohort consisted of 2263 patients, with 1560 classified as obese. GLP-1 RA use was associated with significantly reduced postoperative infection rates [obese: HR = 0.168 (0.086, 0.328), not obese: HR = 0.250 (0.102, 0.612)], fewer revisions [obese: HR = 0.505 (0.368, 0.693), not obese: HR = 0.439 (0.272, 0.708)], decreased postoperative readmission rates [obese: HR = 0.283 (0.243, 0.329), not obese: HR = 0.241 (0.193, 0.301)], and reduced mobility abnormalities [obese: HR = 0.355 (0.230, 0.549), not obese: HR = 0.508 (0.269, 0.959)]. No significant differences were observed in rates of fracture rates between GLP-1 RA users and non-users.
Conclusions: GLP-1 RA use in spinal fusion patients was associated with improved postoperative outcomes, including lower infection rates, fewer revisions, and better quality of life metrics. These findings suggest that GLP-1 RAs may be a valuable adjunctive therapy in managing surgical outcomes in diabetic and obese patients undergoing spinal fusion. Further prospective and animal-based studies are needed to confirm these findings and explore the underlying mechanisms.
Keywords: GLP-1 receptor agonists; diabetes; obesity; postoperative complications; spinal fusion outcomes.
Copyright © 2025 Wolters Kluwer Health, Inc. All rights reserved.
Conflict of interest statement
The authors report no conflicts of interest.
References
-
- Deng H, Yue JK, Ordaz A, Suen CG, Sing DC. Elective lumbar fusion in the United States: national trends in inpatient complications and cost from 2002-2014. J Neurosurg Sci. 2021;65:503–12.
-
- Wang SK, Wang P, Li XY, Kong C, Niu JY, Lu SB. Incidence and risk factors for early and late reoperation following lumbar fusion surgery. J Orthop Surg Res. 2022;17:385.
-
- Moazzeni K, Kazemi KA, Khanmohammad R, Eslamian M, Rostami M, Faghih-Jouibari M. Comparison of surgical outcome between diabetic versus nondiabetic patients after lumbar fusion. Int J Spine Surg. 2018;12:528–32.
-
- Epstein NE. Predominantly negative impact of diabetes on spinal surgery: a review and recommendation for better preoperative screening. Surg Neurol Int. 2017;8:107.
-
- Patel N, Bagan B, Vadera S, et al. Obesity and spine surgery: relation to perioperative complications 2007;6:291–7.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
